🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Kalaris Therapeutics, Inc. (KLRS)
NASDAQ: KLRS · Real-Time Price · USD
1.370
-0.060 (-4.20%)
Nov 18, 2026, 4:00 PM EST - Market closed

Kalaris Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
14.7415.46.691.762.24
Research & Development
32.0930.7545.0411.7111.76
Operating Expenses
46.8346.1551.7313.4614.01
Operating Income
-46.83-46.15-51.73-13.46-14.01
Interest Expense
-1.63-1.63-40.72-1.58-1.03
Other Non Operating Income (Expenses)
5.074.3423.280.340.75
EBT Excluding Unusual Items
-43.4-43.44-69.17-14.7-14.29
Other Unusual Items
-----1.2
Pretax Income
-43.4-43.44-69.17-14.7-15.49
Net Income
-43.4-43.44-69.17-14.7-15.49
Net Income to Common
-43.4-43.44-69.17-14.7-15.49
Net Income Growth
-----
Shares Outstanding (Basic)
2315164
Shares Outstanding (Diluted)
2315164
Shares Change
41.55%1042.87%-77.99%36.56%-
EPS (Basic)
-1.91-2.85-51.77-2.42-3.48
EPS (Diluted)
-1.91-2.85-51.77-2.42-3.48
EPS Growth
-----

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22
Free Cash Flow
--38.57-20.67-14.13-9.78
Free Cash Flow Per Share
--2.53-15.47-2.33-2.20
EBITDA
-46.79-46.14---
D&A For EBITDA
0.040.01---
EBIT
-46.83-46.15-51.73-13.46-14.01